Abstract
A disease-specific measure was needed for use in an international clinical trial to evaluate an investigational drug for genital herpes. A new measure was developed initially in the UK and translated and adapted for use in France, Italy, Germany, Denmark, Spain and the USA. This paper describes the translation and adaptation of the USA measure. It also describes the assessment of internal consistency, reproducibility, content validity, and construct validity (convergent and discriminant) of the measure. Two outcome measures of the final genital herpes-specific measure were developed: (1) a 21-item symptoms subscale; and (2) a 20-item HRQOL subscale. Each measure was scored and analyzed separately; the psychometric testing discussed in this paper refers to the HRQOL subscale only. The internal consistency of the HRQOL subscale is high (r=0.93), as is the reproducibility measured with a two week interval (r=0.85). Convergent validity is moderate to high. (Fleming Self-Regard subscale,r=0.48; SF-36 Social Functioning dimensionr=0.59; SF-36 Mental Health dimensionr=0.50). The number of herpes outbreaks in the past year was a significant predictor of scores on the HRQOL subscale (0–1 outbreaks, mean=82.1; 2+ outbreaks, mean=72.1,p=0.058) suggesting discriminant validity. The measure is currently in a phase III clinical trial including anti-viral therapy where the question of responsiveness can be addressed.
Similar content being viewed by others
References
Johnson R, Lee F, Hadgri A,et al. US genital herpes trends using the first decade of AIDS—prevalences increased in young whites and elevated in blacks (abstract)International Society for STD Research Helsinki, Finland. 1993.
Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections.J Infec Dis 1990;162: 299–305.
Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes.Sex Trans Dis 1990;17: 90.
Corey L. In: Holmes KK, Mardh PA, Sparling PF, Wiesner PJ, eds.Genital Herpes in Sexually Transmitted Diseases. McGraw-Hill Information Services Company, Health Professionals Division. 1989.
Dorsky DI, Crumpacker CS. Drugs 5 years later: Acyclovir.Ann Int Med 1987;107: 859–74.
Drob S. Psychosexual implications of genital herpes.Med Aspects Human Sexuality 1986;20: 97–98.
Luby E and Gillespie O. Psychological response to genital herpes.Helper 1981;3: 2–3.
Bierman SM. A possible psychoneuroimmunologic basis for recurrent genital herpes simplex.Western J Med 1983;139: 547–552.
Drob S, Loemer M, Lifshutz H. Genital herpes: The psychological consequences.Br J Med Psych 1985;58: 307–315.
Longo D, Clum G. Psychosocial factors affecting genital herpes recurrence: linear versus mediating models.J Psychosomatic Res 1989;33: 161–166.
Catotti DN, Clarke P, Catoe KE. Herpes revisited.Sex Trans Dis 1993 March–April:77; 80.
Swanson JM, Chenitz CW. Psychosocial aspects of genital herpes: a review of the literature.Pub Health Nursing 1990;7(2): 96–104.
Wooley PD, Kinghorn GR. Psychological aspects of genital herpes.Stress Med 1985;2: 193–195.
Keller ML, Jadack RA, Mims LF. Perceived stressors and coping responses in persons with recurrent genital herpes.Res Nursing Health 1991;14: 421–430.
Manne S, Sandler I, and Zautra A. Coping and adjustment to genital herpes: Time effects and social support.J Behav Med 1986;9: 163–177.
Goldmeir D, Johnson A, Jefies D, et al. Psychological aspects of recurrences of genital herpes.J Psychosomatic Res 1986;30(5): 601–608.
Carney O, Ross E, Ikkos G, Mindel A. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes.Genitourinary Med 1993;69: 457–459.
Hunt SM. Nottingham Health Profile. In: NK Wenger, ME Mattson, CP Furberg, J Elinson, eds.Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq. 1984.
Stewart A, Ware JE.Measuring functioning and well-being: The medical outcomes study approach. Durham and London: Duke University Press. 1992.
Luby ED, Klinge V. Genital Herpes: A pervasive psychosocial disorder.Arch Derm 1985;121: 494–497.
Hunt SM, McKenna SP. The QLDS: A subscale for the measurement of quality of life in depression.Health Policy 1992;22: 307–319.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes.Drug Info J 1994;28: 19–25.
Fleming JS, Courtney BE. The dimensionality of self-esteem: II. hierarchial facet model for revised measurement subscales.J Personality Social Psych 1984;46(2): 404–421.
Cronbach LJ. Coefficient alpha and the internal structire of tests.Psychometrika. 1951;16: 297–334.
Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures—statistics and strategies for evaluation.Cont Clin Trials 1991;12: 142S-158S.
Author information
Authors and Affiliations
Additional information
This work was carried out at the University of Washington, School of Public Health and Community Medicine and was funded by Burroughs Wellcome and Wellcome UK
Rights and permissions
About this article
Cite this article
Wild, D., Patrick, D., Johnson, E. et al. Measuring health-related quality of life in persons with genital herpes. Qual Life Res 4, 532–539 (1995). https://doi.org/10.1007/BF00634748
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00634748